Literature DB >> 7523168

Granulocyte colony-stimulating factor induces selective elevations of progenitor cells in the peripheral blood of mice.

A W Roberts1, D Metcalf.   

Abstract

The absolute numbers and relative frequencies of progenitor cells in six nonerythroid lineages were monitored in the peripheral blood (PB), bone marrow (BM), and spleen of Balb/c mice during 8 days of granulocyte colony-stimulating factor (G-CSF) injections. G-CSF induced a dose-related increase, up to 570-fold, in progenitor cell numbers in the blood and up to 620-fold rise of these cells in the spleen. The relative frequency of megakaryocyte progenitor cells was significantly increased in the blood compared with values in the BM or spleen. Time-dependent variations were also observed in the relative frequencies of three lineages of progenitor cells in the blood (megakaryocyte, granulocyte, and macrophage), but not in the BM or spleen. The consistent differences induced in the relative frequencies of various progenitor cell types between the blood, marrow, and spleen were independent of G-CSF dose. These data suggest that the increase in progenitor cells in the blood induced by G-CSF cannot simply be explained by a nonselective release of progenitor cells from the marrow or spleen.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523168

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

1.  Imbalance of apoptosis and cell proliferation contributes to the development and persistence of emphysema.

Authors:  Ji-Hyun Lee; Masayuki Hanaoka; Yoshiaki Kitaguchi; Donatas Kraskauskas; Leland Shapiro; Norbert F Voelkel; Laima Taraseviciene-Stewart
Journal:  Lung       Date:  2011-10-21       Impact factor: 2.584

2.  Different effect of granulocyte colony-stimulating factor or bacterial infection on bone-marrow cells of cyclophosphamide-treated or irradiated mice.

Authors:  A M Buisman; T L Van Zwet; J A Langermans; M F Geertsma; P J Leenen; R van Furth
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

3.  STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils.

Authors:  Athanasia D Panopoulos; Ling Zhang; Jonathan W Snow; Daniel M Jones; Amber M Smith; Karim C El Kasmi; Fulu Liu; Mark A Goldsmith; Daniel C Link; Peter J Murray; Stephanie S Watowich
Journal:  Blood       Date:  2006-08-03       Impact factor: 22.113

4.  Effect of stem cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor on morphology of haematopoietic organs in mice.

Authors:  P Szumilas; K Barcew; M Baśkiewicz-Masiuk; B Wiszniewska; M Z Ratajczak; B Machaliński
Journal:  Cell Prolif       Date:  2005-02       Impact factor: 6.831

5.  The absence of Tssc6, a member of the tetraspanin superfamily, does not affect lymphoid development but enhances in vitro T-cell proliferative responses.

Authors:  Jacqueline M Tarrant; Joanna Groom; Donald Metcalf; Ruili Li; Bette Borobokas; Mark D Wright; David Tarlinton; Lorraine Robb
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

6.  Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiation.

Authors:  Ben A Croker; Lisa A Mielke; Sam Wormald; Donald Metcalf; Hiu Kiu; Warren S Alexander; Douglas J Hilton; Andrew W Roberts
Journal:  Exp Hematol       Date:  2008-04-08       Impact factor: 3.084

7.  The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo.

Authors:  Kristy Boyle; Paul Egan; Steven Rakar; Tracy A Willson; Ian P Wicks; Donald Metcalf; Douglas J Hilton; Nicos A Nicola; Warren S Alexander; Andrew W Roberts; Lorraine Robb
Journal:  Blood       Date:  2007-05-17       Impact factor: 22.113

Review 8.  New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim.

Authors:  Michele Ghidini; Jens Claus Hahne; Francesco Trevisani; Stefano Panni; Margherita Ratti; Laura Toppo; Gianluca Tomasello
Journal:  Ther Clin Risk Manag       Date:  2016-06-24       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.